Kimberley Smuga-Otto

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Advances in the scalable production of blood cells from induced pluripotent stem cells (iPSCs) open prospects for the clinical translation of de novo generated blood products, and evoke the need for preclinical evaluation of their efficacy, safety, and immunogenicity in large animal models. Due to substantial similarities with humans, the outcomes of(More)
  • 1